Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA6 | P23280 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12084074 | 0.80 | CCR1 (0.46) | SLC40A1NOS3NOS2CCR1CCR8 | |
| SCHEMBL2565378 | 0.78 | CCR1 (0.44) | SLC40A1NOS3NOS2CCR1CCR8 | |
| SCHEMBL1464583 | 0.78 | ALDH1A1 (0.44) | SLC40A1NOS3NOS2CCR1CCR8 | |
| SCHEMBL12780478 | 0.77 | CCR1 (0.43) | SLC40A1NOS3NOS2CCR1CCR8 | |
| SCHEMBL17647899 | 0.76 | NOS3 (0.43) | NOS3NOS2CA1CA2CA9 | |
| SCHEMBL12780354 | 0.75 | SLC40A1 (0.42) | SLC40A1NOS3NOS2CCR1CCR8 | |
| SCHEMBL8212123 | 0.75 | SLC40A1 (0.53) | SLC40A1CCR1CCR8KDM4EALDH1A1 | |
| SCHEMBL6501463 | 0.74 | CYP3A4 (0.43) | SLC40A1ALDH1A1CA1CA2CA9 | |
| SCHEMBL247456 | 0.74 | CA2 (0.40) | CA1CA2CA9CA12CA6 | |
| SCHEMBL21256375 | 0.74 | CA2 (0.38) | CA1CA2CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016057572-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MILLER MARK THOMAS (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2009133127-A1 | FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS | MERCK SERONO S.A. (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-6890942-B2 | Acyl sulfonamides as inhibitors of HIV integrase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20050004232-A1 | Acyl sulfonamides as inhibitors of HIV integrase | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-06 | — | — | US | disclosed |
| WO-2004103278-A2 | ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004232-A1 | Acyl sulfonamides as inhibitors of HIV integrase | ACSS2, ARSA, ASS1 | SLC40A1 4131/4885NOS3 2493/4885NOS2 2281/4885 |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | SLC40A1 4631/4885NOS3 1983/4885NOS2 2265/4885 |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1B, SLC26A4 | SLC40A1 886/4885NOS3 1722/4885NOS2 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.